Pfizer Limited responded to BSE Limited's email reference L/SURV/ONL/RV/SG/(2026-2027)/59 dated July 17, 2026, seeking clarification regarding a news item titled "Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care" appearing in The Hindu BusinessLine.
The company confirmed that Premarin Vaginal Cream, an imported product, has been temporarily discontinued in India due to certain supply constraints. The company is actively exploring options to restore the supply at the earliest.
Financial impact assessment reveals that Premarin Vaginal Cream contributes less than 1% to the company's revenue. The temporary discontinuation is not expected to have any material impact on the company's financial performance, business operations, or profitability.
Regulatory position: The company determined that this temporary discontinuation did not constitute a material event requiring disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015. Pfizer reaffirmed its commitment to making timely disclosures of all material events and information in accordance with applicable legal and regulatory requirements.
The response was signed by Prajeet Nair, Director – Corporate Services & Company Secretary, on July 17, 2026 at 17:24:51 IST.